This report presents the case of a 78-year-old female with hepatic encephalopathy due to an inferior mesenteric venous-inferior vena cava shunt. She developed hepatocellular carcinoma affected by hepatitis C virus-related cirrhosis and underwent posterior sectionectomy. Portal vein thrombosis developed and the portal trunk was narrowed after hepatectomy. Portal vein thrombosis resulted in high ...

OBJECTIVE To determine the frequency of protein C, protein S and antithrombin deficiency, and factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations in children and adolescents with portal vein thrombosis, as well as assessing the hereditary character of this disorders. METHODS A two-year study was carried out to determine the frequency of thrombophilic ...

UNLABELLED There are few reported cases of cavernous transformation of the portal vein (CTPV) in adults. We present a case of a 58 year-old male who was found to have this complication due to portal vein thrombosis (PVT). A 58-year old African American male with chronic alcohol and tobacco use presented with a 25-day history of weakness, generalized malaise, nausea and vomiting associated with ...

Portal vein tumor thrombus (PVTT) is a complication of hepatocellular carcinoma (HCC). Our aim was to determine if sorafenib given postoperatively prolongs the survival of HCC patients with PVTT who undergo hepatic resection. Between 2009 and 2013 advanced HCC with PVTT who underwent surgical resection were given the option to take sorafenib postoperatively. Overall survival (OS) and disease-fr...

Background and Study Aims: Portal vein thrombosis (PVT) associated with untreated HCC are almost always malignant, still benign portal vein thrombus should be considered as well, This study was designed to study the value of ultrasound-guided fine needle aspiration cytology in the differential diagnosis of portal vein thrombosis. Patients and Methods: This study included 20 patients with chroni...

Background and aim: Hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) is traditionally considered a contraindication for liver transplantation (LT). Successful downstaging has been shown to improve survival. Limited data have promising results the use of immune check point inhibitor like nivolumab downstage these patients transplantation. The novel combination checkpoint atezoliz...

The present study aimed to identify the risk factors influencing the survival of patients with hepatocellular carcinoma (HCC) affected by portal vein tumor thrombus (PVTT), following hepatic resection, and to establish a prognostic model. Between March 2001 and May 2008, 234 cases of HCC with PVTT that underwent hepatic resection were randomly divided into experimental or validation groups. The...

PURPOSE Numerous studies have tried to combine transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) with radiotherapy (RT) for the treatment of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT). However, the efficacy of TACE or HAIC combined with RT versus TACE or HAIC alone remains controversial. Thus, we performed a meta-analysis...